Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Voluven

Phase 3Small molecule

RRegional Hospital Holstebro

Voluven is one of 99 small molecule programs targeting Ischemia. It is currently in Phase 3.

3

Indications

10

Total Trials

0

Active Trials

98

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

AnemiaActive, not recruiting

HypotensionActive, not recruiting

IschemiaPhase 2

Active, not recruiting

AnemiaPreclinical

Active, not recruiting

HypotensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Anemia

#DrugCompanyPhaseTrials

Rituxan

Ultomiris

Feosol

AAuerbach Hematology Oncology Associates P C

Soliris

Cytoxan

BBaxter Healthcare Corporation

Campath

GGenzyme, a Sanofi Company

LNP023

GSK1278863

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Aranesp

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypotension3 trials

Different Preloads for Prevention of Hypotension in Patients Undergoing Elective CS Under Intrathecal Anesthesia

Unknown status·—·Phase 1·NCT03465943·60 enrolled

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Completed·SSangart·Phase 3·NCT00420277·462 enrolled

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Completed·SSangart·Phase 3·NCT00421200·375 enrolled

Anemia1 trial

Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty

Terminated·RRigshospitalet, Denmark·N/A·NCT01452581·5 enrolled

Coronary Revascularization1 trial

Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization

Completed·BBiopure Corporation·Phase 2·NCT00317512·45 enrolled

Neurosurgery1 trial

Fluid Optimization With Crystalloids and Colloids in Neurosurgery

Completed·UUniversity Medical Centre Ljubljana·N/A·NCT03249298·80 enrolled

Laparoscopic1 trial

Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy

Terminated·RRegional Hospital Holstebro·Phase 4·NCT01486550·14 enrolled

3 more indications

Ischemia1 trial

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Completed·SSangart·Phase 2·NCT00633659·6 enrolled

Prostatectomy1 trial

Hydroxyethyl Starch and Renal Function After Radical Prostatectomy

Completed·RRegional Hospital Holstebro·Phase 4·NCT01486563·40 enrolled

Hip Replacement Surgery1 trial

Hydroxyethyl Starch and Renal Function After Hip Replacement Surgery

Completed·RRegional Hospital Holstebro·Phase 4·NCT01486576·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Voluven. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Voluven compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Voluven. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regional Hospital Holstebro company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRegional Hospital Holstebro

Related News